|
Biomimetic HDL Nanoparticles for Treatment of Cancer, Immune and Inflammatory Disorders, and Cardiovascular Disease
SHORT DESCRIPTION
Self-assembling biomimetic high-density lipoprotein nanoparticle (HDL NP) platform technology with a soft organic core, designed to more closely replicate key functional properties of mature human HDL for therapeutic use in cardiovascular disease, cancer, and inflammatory/immune disorders.
INVENTORS
Colby Thaxton*
Northwestern...
Published: 6/16/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s): Atherosclerosis, Autoimmune disease, BIO2026, Breast cancer, Cancer/Oncology, Cardiology and Cardiovascular disease, Gene therapy, Immunology, Immunotherapy, Inflammation, Nanomaterials, Nanoparticle, Nanotechnology, Nucleic Acids, Platform technology, Prostate cancer, Research tool, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Healthcare Devices, Tools & IT, Life Sciences > Therapeutics
|
|
Inhibitors of MNK Kinase for Targeted Cancer and CNS Therapeutics
NU 2015-098 (NU 2015-098, NU 2018-036, NU 2025-036)
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
SHORT DESCRIPTION
MNK kinase inhibitors that reduce cancer cell viability and proliferation and penetrates the brain for potential treatment of glioblastoma and CNS disorders.
BACKGROUND
Leukemia and brain...
Published: 6/16/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, AML - Acute myeloid leukemia, ASD - Autism Spectrum Disorder, BIO2026, Bladder cancer, Brain cancer, Breast cancer, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Lung cancer, Neurodegenerative disease, Pancreatic cancer, Prostate cancer, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Use of Nucleotide Synthesis Inhibitors for Targeted Therapy in MLL3/4 COMPASS Mutant Cancer
NU 2022-053
INVENTORS
Ali Shilatifard (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
Zibo Zhao (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
SHORT DESCRIPTION
A therapeutic platform that targets MLL3/4 COMPASS mutant cancers by using nucleotide synthesis inhibitors to disrupt...
Published: 6/16/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s): BIO2026, Bladder cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Leukemia, Lung cancer, Lymphoma, Prostate cancer, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment
SHORT DESCRIPTION
Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma.
INVENTORS
Amy Heimberger*
Northwestern University Feinberg School of Medicine, Department of Neurological Surgery
* Principal Investigator
NU Tech ID: NU 2025-212
IP...
Published: 6/16/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, BIO2026, Bladder cancer, Brain cancer, Breast cancer, Cancer Treatment, Cancer/Oncology, Cervical cancer, CNS - Central Nervous System, Colon cancer, Drug delivery, Endometrial cancer, Gastric cancer, GBM - Glioblastoma, Head and neck cancer, Immunology, Immunotherapy, Liver cancer, Lung cancer, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, Ovarian cancer, Pancreatic cancer, PD - Parkinson's Disease, Prostate cancer, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 6/16/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Northwestern University Feinberg School of Medicine, Department of Urology
Gary Schiltz (PI)*
Weinberg College of Arts and Sciences, Department of Chemistry
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate...
Published: 6/16/2026
|
Updated: 2/3/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Clinical Bacterial Isolate Engineered as Prostate Cancer Immunotherapy
NU 2015-087
INVENTORS
Praveen Thumbikat*
Anthony Schaeffer
Jonathan Anker
Sarki Abdulkadir
SHORT DESCRIPTION
This technology uses a genetically modified CP1 E. coli as an immunotherapeutic agent for prostate cancer. It offers a non-invasive treatment option designed to stimulate an immune response in both early stage and advanced disease.
BACKGROUND
Prostate...
Published: 6/16/2026
|
Updated: 10/10/2025
|
Inventor(s):
Keywords(s): BIO2026, Biologic, Cancer/Oncology, Immunotherapy, Prostate cancer, Synthetic biology, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
IDO-PROTACs for Improving the Anti-Cancer Immune Response
NU 2020-137
INVENTORS
Derek Wainwright*
Gary Schiltz
SHORT DESCRIPTION
IDO-PROTAC that target immunosuppressive IDO activity via degradation
ABSTRACT
The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy, chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 6/16/2026
|
Updated: 5/27/2022
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Brain cancer, Cancer/Oncology, Colon cancer, Endometrial cancer, Immunotherapy, Pancreatic cancer, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|